Published in N Engl J Med on September 11, 2003
Rehabilitation of Patients With Atrial Fibrillation | NCT03035539
The net clinical benefit of warfarin anticoagulation in atrial fibrillation. Ann Intern Med (2009) 4.71
Guidelines for the primary prevention of stroke: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke (2014) 3.48
Summary of evidence-based guideline update: prevention of stroke in nonvalvular atrial fibrillation: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology (2014) 3.36
Genetic variants associated with warfarin dose in African-American individuals: a genome-wide association study. Lancet (2013) 3.21
ADHD drugs and serious cardiovascular events in children and young adults. N Engl J Med (2011) 3.12
Warfarin pharmacogenetics. Pharmacotherapy (2008) 2.50
Death and disability from warfarin-associated intracranial and extracranial hemorrhages. Am J Med (2007) 2.16
Anticoagulation intensity and outcomes among patients prescribed oral anticoagulant therapy: a systematic review and meta-analysis. CMAJ (2008) 2.02
The prevalence of and factors associated with chronic atrial fibrillation in Medicare/Medicaid-eligible dialysis patients. Kidney Int (2011) 1.79
Intracerebral haemorrhage: an often neglected medical emergency. Intern Emerg Med (2007) 1.55
Race- and sex-related differences in care for patients newly diagnosed with atrial fibrillation. Heart Rhythm (2015) 1.55
Age and the risk of warfarin-associated hemorrhage: the anticoagulation and risk factors in atrial fibrillation study. J Am Geriatr Soc (2006) 1.51
Five-year neurodevelopmental outcome of neonatal dehydration. J Pediatr (2007) 1.47
Frequency of adverse events in patients with poor anticoagulation: a meta-analysis. CMAJ (2007) 1.29
Should patient characteristics influence target anticoagulation intensity for stroke prevention in nonvalvular atrial fibrillation?: the ATRIA study. Circ Cardiovasc Qual Outcomes (2009) 1.29
Current issues in patient adherence and persistence: focus on anticoagulants for the treatment and prevention of thromboembolism. Patient Prefer Adherence (2010) 1.26
The future of warfarin pharmacogenetics in under-represented minority groups. Future Cardiol (2012) 1.25
Withdrawal of antithrombotic agents and its impact on ischemic stroke occurrence. Stroke (2011) 1.17
Role of pharmacogenomics in the management of traditional and novel oral anticoagulants. Pharmacotherapy (2011) 1.16
The ABC (age, biomarkers, clinical history) stroke risk score: a biomarker-based risk score for predicting stroke in atrial fibrillation. Eur Heart J (2016) 1.14
Thirty-day mortality after ischemic stroke and intracranial hemorrhage in patients with atrial fibrillation on and off anticoagulants. Stroke (2012) 1.10
Novel oral anticoagulants versus warfarin therapy at various levels of anticoagulation control in atrial fibrillation--a cost-effectiveness analysis. J Gen Intern Med (2013) 1.09
Pharmacogenetics and cardiovascular disease--implications for personalized medicine. Pharmacol Rev (2013) 1.04
Influence of CYP2C9 and VKORC1 on warfarin response during initiation of therapy. Blood Cells Mol Dis (2009) 1.02
Association of the GGCX (CAA)16/17 repeat polymorphism with higher warfarin dose requirements in African Americans. Pharmacogenet Genomics (2012) 1.02
Occurrence and quality of anticoagulant treatment of chronic atrial fibrillation in primary health care in Sweden: a retrospective study on electronic patient records. BMC Clin Pharmacol (2004) 0.99
Current and future concepts in stroke prevention. CMAJ (2004) 0.99
2014 AATS guidelines for the prevention and management of perioperative atrial fibrillation and flutter for thoracic surgical procedures. J Thorac Cardiovasc Surg (2014) 0.99
Real-life use of Rivaroxaban in the Netherlands: data from the Xarelto for Prevention of Stroke in Patients with Atrial Fibrillation (XANTUS) registry. Neth Heart J (2017) 0.95
Contemporary management of atrial fibrillation: update on anticoagulation and invasive management strategies. Mayo Clin Proc (2009) 0.93
Coagulation assessment with the new generation of oral anticoagulants. Emerg Med J (2015) 0.93
Self-management of oral anticoagulation in nonvalvular atrial fibrillation (SMAAF study). Z Kardiol (2005) 0.93
Cost-effectiveness of dabigatran versus genotype-guided management of warfarin therapy for stroke prevention in patients with atrial fibrillation. PLoS One (2012) 0.93
Quality of vitamin K antagonist control and outcomes in atrial fibrillation patients: a meta-analysis and meta-regression. Thromb J (2014) 0.92
Risk factor management to prevent first stroke. Neurol Clin (2008) 0.92
Predictors of occult paroxysmal atrial fibrillation in cryptogenic strokes detected by long-term noninvasive cardiac monitoring. Stroke Res Treat (2011) 0.89
Warfarin therapy: in need of improvement after all these years. Expert Opin Pharmacother (2008) 0.88
Cost-effectiveness of clopidogrel-aspirin versus aspirin alone for acute transient ischemic attack and minor stroke. J Am Heart Assoc (2014) 0.88
Antithrombotic medication for cardioembolic stroke prevention. Stroke Res Treat (2011) 0.87
Stroke prevention in atrial fibrillation: understanding the new oral anticoagulants dabigatran, rivaroxaban, and apixaban. Thrombosis (2012) 0.87
Dabigatran in atrial fibrillation: pharmacology and clinical trials. J Interv Card Electrophysiol (2011) 0.87
Efficacy and safety of vitamin K-antagonists (VKA) for atrial fibrillation in non-dialysis dependent chronic kidney disease. PLoS One (2014) 0.86
Predictors of the risk of falls among elderly with chronic atrial fibrillation. Clinics (Sao Paulo) (2012) 0.86
Atrial fibrillation and stroke prevention. N Engl J Med (2003) 0.86
Patterns of warfarin use and subsequent outcomes in atrial fibrillation in primary care practices. Vasc Health Risk Manag (2012) 0.85
Relationship between time in therapeutic range and comparative treatment effect of rivaroxaban and warfarin: results from the ROCKET AF trial. J Am Heart Assoc (2014) 0.85
Consistency of safety and efficacy of new oral anticoagulants across subgroups of patients with atrial fibrillation. PLoS One (2014) 0.84
Atrial Fibrillation and Hypertension: Mechanistic, Epidemiologic, and Treatment Parallels. Methodist Debakey Cardiovasc J (2016) 0.83
Long-term survival after ischemic stroke in patients with atrial fibrillation. Neurology (2014) 0.83
Role of cytochrome P450 genotype in the steps toward personalized drug therapy. Pharmgenomics Pers Med (2011) 0.83
Vitamin E serum levels and bleeding risk in patients receiving oral anticoagulant therapy: a retrospective cohort study. J Am Heart Assoc (2013) 0.83
[Anticoagulation with atrial fibrillation]. Herzschrittmacherther Elektrophysiol (2006) 0.82
Management of postoperative atrial fibrillation. J Anesth (2012) 0.82
Battle of oral anticoagulants in the field of atrial fibrillation scrutinized from a clinical practice (the real world) perspective. Thromb J (2011) 0.82
Cost-effectiveness of rivaroxaban versus warfarin for stroke prevention in atrial fibrillation in the Belgian healthcare setting. Pharmacoeconomics (2013) 0.82
Stroke prevention with oral anticoagulation in older people with atrial fibrillation - a pragmatic approach. Aging Dis (2012) 0.82
Automatic online detection of atrial fibrillation based on symbolic dynamics and Shannon entropy. Biomed Eng Online (2014) 0.82
Out-of-range INR values and outcomes among new warfarin patients with non-valvular atrial fibrillation. Int J Clin Pharm (2014) 0.81
Structure and markers of appropriateness, quality and performance of drug treatment over a 1-year period after hospital discharge in a cohort of elderly patients with cardiovascular diseases from Germany. Eur J Clin Pharmacol (2004) 0.81
Are the novel anticoagulants better than warfarin for patients with atrial fibrillation? J Thorac Dis (2015) 0.81
Can we improve outcomes in AF patients by early therapy? BMC Med (2009) 0.81
Stroke in atrial fibrillation--hope on the horizon? J R Soc Interface (2010) 0.81
Evidence-based percutaneous closure of the left atrial appendage in patients with atrial fibrillation. Curr Cardiol Rev (2012) 0.81
The clinical efficacy of dabigatran etexilate for preventing stroke in atrial fibrillation patients. Vasc Health Risk Manag (2013) 0.81
APOE ε variants increase risk of warfarin-related intracerebral hemorrhage. Neurology (2014) 0.80
Influence of kidney function on risk of supratherapeutic international normalized ratio-related hemorrhage in warfarin users: a prospective cohort study. Am J Kidney Dis (2014) 0.80
Stroke propensity is increased under atrial fibrillation hemodynamics: a simulation study. PLoS One (2013) 0.80
Direct vitamin K antagonist anticoagulant treatment health care costs in patients with non-valvular atrial fibrillation. BMC Health Serv Res (2014) 0.80
Oral direct factor Xa inhibitors for stroke prevention in atrial fibrillation. Nat Rev Cardiol (2012) 0.80
Effectiveness and safety of warfarin and anti-platelet drugs for the primary prevention of stroke in patients with non-valvular atrial fibrillation: a meta-analysis. Int J Clin Exp Med (2015) 0.80
[New oral anticoagulants for the prevention of stroke. Open questions in geriatric patients]. Z Gerontol Geriatr (2012) 0.79
Atrial fibrillation is a major risk factor for stroke, especially in women: the Jichi Medical School cohort study. J Epidemiol (2011) 0.79
Anticoagulation in Patients Aged ≥75 years with Atrial Fibrillation: Role of Novel Oral Anticoagulants. Cardiol Ther (2013) 0.79
Cardioembolic stroke in atrial fibrillation-rationale for preventive closure of the left atrial appendage. Korean Circ J (2009) 0.79
CHA(2)DS(2)-VASc score and prognosis in ischemic strokes with atrial fibrillation. J Neurol (2011) 0.79
Trends in Oral Anticoagulation Therapy Among Korean Patients With Atrial Fibrillation: The KORean Atrial Fibrillation Investigation. Korean Circ J (2012) 0.78
Oral anticoagulation in elderly patients as secondary prevention of cardioembolic strokes. Int Arch Med (2010) 0.78
Management of stroke prevention in canadian patients with atrial fibrillation at moderate to high risk of stroke. Can J Hosp Pharm (2013) 0.78
Childhood basilar artery occlusion: a report of 5 cases and review of the literature. J Child Neurol (2013) 0.77
Prescription patterns of oral anticoagulants for patients with non-valvular atrial fibrillation: experience at a Japanese single institution. Heart Vessels (2015) 0.77
Limited clinical utility of genotype-guided warfarin initiation dosing algorithms versus standard therapy: a meta-analysis and trial sequential analysis of 11 randomized controlled trials. Pharmacogenomics J (2015) 0.77
High prevalence of modifiable stroke risk factors identified in a pharmacy-based screening programme. Open Heart (2016) 0.77
Warfarin dose requirements in a patient with the CYP2C9*14 allele. Pharmacogenomics (2014) 0.77
Secondary stroke prevention strategies for the oldest patients: possibilities and challenges. Drugs Aging (2009) 0.77
A Real-Time Atrial Fibrillation Detection Algorithm Based on the Instantaneous State of Heart Rate. PLoS One (2015) 0.77
New oral anticoagulants: are coagulation units still required? Thromb J (2014) 0.77
Oral anticoagulation to reduce risk of stroke in patients with atrial fibrillation: current and future therapies. Clin Interv Aging (2013) 0.77
Practical Issues to Prevent Stroke Associated with Non-valvular Atrial Fibrillation. J Stroke (2013) 0.77
How to choose appropriate direct oral anticoagulant for patient with nonvalvular atrial fibrillation. Ann Hematol (2015) 0.77
12/15-Lipoxygenase Inhibition or Knockout Reduces Warfarin-Associated Hemorrhagic Transformation After Experimental Stroke. Stroke (2017) 0.76
Telephone-based anticoagulation management in the homebound setting: a retrospective observational study. Int J Gen Med (2013) 0.76
The use of antithrombotics in patients presenting with stroke and atrial fibrillation. Ther Clin Risk Manag (2007) 0.76
Cost-effectiveness of thrombolysis within 4.5 hours of acute ischemic stroke in China. PLoS One (2014) 0.76
Heart disease and stroke statistics--2012 update: a report from the American Heart Association. Circulation (2011) 31.98
Heart disease and stroke statistics--2013 update: a report from the American Heart Association. Circulation (2012) 30.79
Heart disease and stroke statistics--2011 update: a report from the American Heart Association. Circulation (2010) 30.07
Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med (2011) 28.99
Heart disease and stroke statistics--2014 update: a report from the American Heart Association. Circulation (2013) 28.02
Heart disease and stroke statistics--2015 update: a report from the American Heart Association. Circulation (2014) 22.74
Heart Disease and Stroke Statistics-2016 Update: A Report From the American Heart Association. Circulation (2015) 10.14
Population trends in the incidence and outcomes of acute myocardial infarction. N Engl J Med (2010) 8.28
Ethnic disparities in diabetic complications in an insured population. JAMA (2002) 8.28
Criteria for evaluation of novel markers of cardiovascular risk: a scientific statement from the American Heart Association. Circulation (2009) 8.11
The Chronic Renal Insufficiency Cohort (CRIC) Study: Design and Methods. J Am Soc Nephrol (2003) 7.79
Large-scale association analysis identifies new risk loci for coronary artery disease. Nat Genet (2012) 7.59
Body mass index and risk for end-stage renal disease. Ann Intern Med (2006) 7.56
FGF23 induces left ventricular hypertrophy. J Clin Invest (2011) 7.22
Executive summary: heart disease and stroke statistics--2014 update: a report from the American Heart Association. Circulation (2014) 6.55
Executive summary: heart disease and stroke statistics--2012 update: a report from the American Heart Association. Circulation (2012) 6.24
Executive summary: heart disease and stroke statistics--2013 update: a report from the American Heart Association. Circulation (2013) 6.13
Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation. Circulation (2007) 5.89
Dialysis-requiring acute renal failure increases the risk of progressive chronic kidney disease. Kidney Int (2009) 5.28
Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: the PRIMO randomized controlled trial. JAMA (2012) 5.27
The "gender gap" in authorship of academic medical literature--a 35-year perspective. N Engl J Med (2006) 5.23
A new risk scheme to predict warfarin-associated hemorrhage: The ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study. J Am Coll Cardiol (2011) 5.06
APOL1 risk variants, race, and progression of chronic kidney disease. N Engl J Med (2013) 5.00
Risk of thromboembolism with short-term interruption of warfarin therapy. Arch Intern Med (2008) 4.83
The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. N Engl J Med (1990) 4.77
The net clinical benefit of warfarin anticoagulation in atrial fibrillation. Ann Intern Med (2009) 4.71
Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation. Ann Intern Med (2010) 4.16
Chronic Renal Insufficiency Cohort (CRIC) Study: baseline characteristics and associations with kidney function. Clin J Am Soc Nephrol (2009) 4.16
Association of prehospital advanced airway management with neurologic outcome and survival in patients with out-of-hospital cardiac arrest. JAMA (2013) 4.14
Anticoagulation therapy for stroke prevention in atrial fibrillation: how well do randomized trials translate into clinical practice? JAMA (2003) 4.13
Risk factors for end-stage renal disease: 25-year follow-up. Arch Intern Med (2009) 4.05
Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest (2008) 4.01
Why don't diabetes patients achieve recommended risk factor targets? Poor adherence versus lack of treatment intensification. J Gen Intern Med (2008) 3.99
Reducing delay in seeking treatment by patients with acute coronary syndrome and stroke: a scientific statement from the American Heart Association Council on cardiovascular nursing and stroke council. Circulation (2006) 3.93
Effect of age on stroke prevention therapy in patients with atrial fibrillation: the atrial fibrillation investigators. Stroke (2009) 3.89
Defining patient complexity from the primary care physician's perspective: a cohort study. Ann Intern Med (2011) 3.83
Improved blood pressure control associated with a large-scale hypertension program. JAMA (2013) 3.80
Causes of death for patients with community-acquired pneumonia: results from the Pneumonia Patient Outcomes Research Team cohort study. Arch Intern Med (2002) 3.78
Therapy modifications in response to poorly controlled hypertension, dyslipidemia, and diabetes mellitus. Ann Intern Med (2006) 3.71
Long-term outcomes of surgical and nonsurgical management of lumbar spinal stenosis: 8 to 10 year results from the maine lumbar spine study. Spine (Phila Pa 1976) (2005) 3.67
Mortality among homeless adults in Boston: shifts in causes of death over a 15-year period. JAMA Intern Med (2013) 3.67
The effect of warfarin and intensity of anticoagulation on outcome of intracerebral hemorrhage. Arch Intern Med (2004) 3.63
A controlled trial of web-based diabetes disease management: the MGH diabetes primary care improvement project. Diabetes Care (2003) 3.57
Video decision support tool for advance care planning in dementia: randomised controlled trial. BMJ (2009) 3.55
Prevention of atrial fibrillation: report from a national heart, lung, and blood institute workshop. Circulation (2009) 3.50
Translating the results of randomized trials into clinical practice: the challenge of warfarin candidacy among hospitalized elderly patients with atrial fibrillation. Stroke (2006) 3.49
Geographic variation in cardiovascular procedure use among Medicare fee-for-service vs Medicare Advantage beneficiaries. JAMA (2013) 3.30
Nonrecovery of kidney function and death after acute on chronic renal failure. Clin J Am Soc Nephrol (2009) 3.28
Phosphorus binders and survival on hemodialysis. J Am Soc Nephrol (2008) 3.26
Long-term outcomes of surgical and nonsurgical management of sciatica secondary to a lumbar disc herniation: 10 year results from the maine lumbar spine study. Spine (Phila Pa 1976) (2005) 3.17
Can patients be anticoagulated after intracerebral hemorrhage? A decision analysis. Stroke (2003) 3.12
Antithrombotic therapy in atrial fibrillation: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest (2004) 3.11
Tests of glycemia for the diagnosis of type 2 diabetes mellitus. Ann Intern Med (2002) 3.06
Advanced age, anticoagulation intensity, and risk for intracranial hemorrhage among patients taking warfarin for atrial fibrillation. Ann Intern Med (2004) 3.06
Patient-physician connectedness and quality of primary care. Ann Intern Med (2009) 3.01
Incidence and prognosis of resistant hypertension in hypertensive patients. Circulation (2012) 2.99
Impact of activated vitamin D and race on survival among hemodialysis patients. J Am Soc Nephrol (2008) 2.96
Oral anticoagulants vs aspirin in nonvalvular atrial fibrillation: an individual patient meta-analysis. JAMA (2002) 2.94
Comparison of risk stratification schemes to predict thromboembolism in people with nonvalvular atrial fibrillation. J Am Coll Cardiol (2008) 2.93
Elevated blood pressure and risk of end-stage renal disease in subjects without baseline kidney disease. Arch Intern Med (2005) 2.90
Evidence of focal small-fiber axonal degeneration in complex regional pain syndrome-I (reflex sympathetic dystrophy). Pain (2006) 2.87
Executive Summary: Heart Disease and Stroke Statistics-2016 Update: A Report From the American Heart Association. Circulation (2016) 2.87
Presence and acquired origin of reduced recall for fear extinction in PTSD: results of a twin study. J Psychiatr Res (2008) 2.78
Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of ROCKET AF. Lancet Neurol (2012) 2.77
ADHD medications and risk of serious cardiovascular events in young and middle-aged adults. JAMA (2011) 2.77
Missed appointments and poor glycemic control: an opportunity to identify high-risk diabetic patients. Med Care (2004) 2.73
Prediction of functional outcome in patients with primary intracerebral hemorrhage: the FUNC score. Stroke (2008) 2.72
Susceptibility locus for clinical and subclinical coronary artery disease at chromosome 9p21 in the multi-ethnic ADVANCE study. Hum Mol Genet (2008) 2.71
Racial variation in the prevalence of atrial fibrillation among patients with heart failure: the Epidemiology, Practice, Outcomes, and Costs of Heart Failure (EPOCH) study. J Am Coll Cardiol (2004) 2.68
New prescription medication gaps: a comprehensive measure of adherence to new prescriptions. Health Serv Res (2009) 2.63
The relationship between daily atrial tachyarrhythmia burden from implantable device diagnostics and stroke risk: the TRENDS study. Circ Arrhythm Electrophysiol (2009) 2.59
Cohort Profile: The Diabetes Study of Northern California (DISTANCE)--objectives and design of a survey follow-up study of social health disparities in a managed care population. Int J Epidemiol (2008) 2.59
Incident atrial fibrillation and risk of end-stage renal disease in adults with chronic kidney disease. Circulation (2012) 2.56
Transplant nephrectomy improves survival following a failed renal allograft. J Am Soc Nephrol (2009) 2.56
Health-related quality of life and estimates of utility in chronic kidney disease. Kidney Int (2005) 2.54
Racial/ethnic variation in asthma status and management practices among children in managed medicaid. Pediatrics (2002) 2.54
Commonly used surrogates for baseline renal function affect the classification and prognosis of acute kidney injury. Kidney Int (2009) 2.53
Clinician support and psychosocial risk factors associated with breastfeeding discontinuation. Pediatrics (2003) 2.49
An effective approach to high blood pressure control: a science advisory from the American Heart Association, the American College of Cardiology, and the Centers for Disease Control and Prevention. J Am Coll Cardiol (2013) 2.47
Longitudinal study of new and prevalent use of self-monitoring of blood glucose. Diabetes Care (2006) 2.44